 Connection
Stephen Kissler to Aged
This is a "connection" page, showing publications Stephen Kissler has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.082 |
|
|
|
-
Kohli M, Maschio M, Lee A, Kissler S, Carroll S, van de Velde N, Beck E, Balogh O, Joshi K. The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model. Vaccine. 2026 Jul 11; 85:128687.
Score: 0.015
-
Kline MC, Kissler SM, Whittles LK, Barnett ML, Grad YH. Spatiotemporal Trends in Group A Streptococcal Pharyngitis in the United States. Clin Infect Dis. 2024 05 15; 78(5):1345-1351.
Score: 0.013
-
Wilcock AD, Kissler S, Mehrotra A, McGarry BE, Sommers BD, Grabowski DC, Grad YH, Barnett ML. Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population. JAMA Health Forum. 2024 01 05; 5(1):e235044.
Score: 0.012
-
Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, Connolly S, Anderson DJ, Khullar G, MacKay M, Patel M, Kelly S, Manhertz A, Eiter I, Salgado D, Baker T, Howard B, Dudley JT, Mason CE, Nair M, Huang Y, DiFiori J, Ho DD, Grubaugh ND, Grad YH. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. Elife. 2022 11 16; 11.
Score: 0.011
-
Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, Buckee CO, Grad YH. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. Elife. 2021 03 05; 10.
Score: 0.010
-
Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, Larremore DB. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 02 26; 371(6532):916-921.
Score: 0.010
-
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhäberle E, Minckwitz GV, Loibl S, Holtrich U, Kaufmann M. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 2007 Jun; 16(3):235-40.
Score: 0.004
-
Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007 Feb; 16(1):86-93.
Score: 0.004
-
Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, Solbach C, Kiesel L, Jackisch C. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncol Rep. 2004 Oct; 12(4):695-9.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|